共 50 条
- [31] First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with PsoriasisPLOS ONE, 2015, 10 (08):Gottlieb, Alice B.Krueger, James G.Lundblad, Mia SandbergGothberg, MarieSkolnick, Brett E.
- [32] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Ganju, VinodCooper, AdamGao, BoWilkinson, Kate
- [33] First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors (vol 14, 1376551, 2024)FRONTIERS IN ONCOLOGY, 2025, 14Shimizu, ToshioPowderly, JohnAbdul Razak, AlbiruniLorusso, PatriciaMiller, Kathy D.Kao, StevenKongpachith, SarahTribouley, CatherineGraham, MichelleStoll, BrianPatel, MaulikSahtout, MohammadBlaney, MarthaLeibman, RachelGolan, TaliaTolcher, Anthony
- [34] A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009,a Novel Bsab Dual Targeting PD-1 x CD47,in Patients with EBV plus Non-Hodgkin Lymphoma (NHL)BLOOD, 2024, 144 : 1741 - 1742Gui, LinZhou, KeshuLiu, TingQin, YanJing, HongmeiLi, WenyuLi, YajunHuang, WenrongWang, ZhenSun, XiuhuaLi, QuanZhang, FamingLi, HenryZhang, LeiSun, PengGao, XinbaoShi, Yuankai
- [35] Phase I dose-escalation and cohort expansion study of the anti-BTLA antibody, tifcemalimab, in combination with toripalimab (anti-PD-1) in heavily pretreated patients (pts) with advanced malignanciesJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Ma, Vincent T.Milhem, Mohammed M.Hidalgo, ManuelShields, Anthony F.Segar, Jennifer MargaretKhalil, MayaDavis, Andrew A.Verschraegen, Claire F.Wong, Deborah J. L.Schilder, Russell J.Gao, XinPowderly, John D., IIJiang, YixingAggarwal, Rahul RajAwan, Farrukh TauseefMcKean, MeredithChow, Warren AllenYao, ShengKeegan, PatriciaNaing, Aung
- [36] Interim results of phase I dose escalation study of YBL-006: A novel anti-PD-1 monoclonal antibody in advanced solid tumorsANNALS OF ONCOLOGY, 2021, 32 : S838 - S838Lee, K-W.Park, J.Oh, D-Y.Kim, S. H.Sabanathan, D.Kim, T. M.Kim, M.Yoon, J.Lee, H.Park, S.Paeng, K.Ock, C-Y.
- [37] Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignanciesJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):Naing, AungInfante, JeffreyGoel, SanjayBurris, HowardBlack, ChelseaMarshall, ShannonAchour, IkbelBarbee, SusannahMay, RenaMorehouse, ChrisPollizzi, KristenSong, XuyangSteele, KeithElgeioushi, NairouzWalcott, FarzanaKarakunnel, JoysonLoRusso, PatriciaWeise, AmyEder, JosephCurti, BrendanOberst, Michael
- [38] A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Ullenhag, Gustav J.Yachnin, JeffreyCarneiro, AnaElison, EmmaCarlsson, MalinRussell, Charlotte AstridSmith, Karin Enell
- [39] Phase I study of anti-PD1 in combination with low-dose decitabine in patients with advanced and untreated malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Wang, ChunmengLiu, YangZhang, WenyingChen, MeixiaShi, LuDong, LiangLi, XiangYang, QingmingNie, JingHan, WeiDong
- [40] CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumoursBJC Reports, 3 (1):J. Randolph HechtJean-Marie MichotDavid BajorAmita PatnaikKi Y. ChungJudy WangGerald FalchookJames M. ClearyRichard KimAnuradha KrishnamurthyOmkar MaratheHagop YoussoufianCatherine EllisAngela WaszakSrimoyee GhoshHailei ZhangKaitlin YablonskiShruti D. ShahIvan Diaz-PadillaSusanna Ulahannan